Axcan files Photofrin sNDA for Barrett’s esophagus
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Axcan supplemental NDA for Photofrin (porfimer photodynamic therapy) for treatment of high-grade dysplasia associated with Barrett's esophagus is granted orphan drug status. The filing is based on a 208-patient Phase III study showing ablation of dysplasia in 72% of patients using Photofrin plus oral omeprazole (AstraZeneca's Prilosec) vs. 31% for omeprazole alone (p<0.0001). A trend toward reduction of progression to esophageal cancer was also seen, with a 9.4% progression rate for Photofrin plus omeprazole vs. 18.6% for omeprazole. Photofrin is currently approved for use in esophageal, lung and bladder cancer
You may also be interested in...
Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
COVID-19 Will Forever Change Workplace, But Not Necessarily For The Better, Merck’s Frazier Says
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: